Immunoliposomes: A promising approach to targeting cancer therapy

BioDrugs

Volumn 15, Issue 4, 2001, Pages 215-224

  Bendas, G ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ENZYME; EPITOPE; FENRETINIDE; FLOXURIDINE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; MACROGOL; PRODRUG; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; CANCER CHEMOTHERAPY; CANCER THERAPY; CLEARANCE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG RELEASE; DRUG TARGETING; GENE THERAPY; GENE TRANSFER; HALF LIFE TIME; HUMAN; IMMUNOGENICITY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEREOCHEMISTRY; SYNTHESIS; TECHNIQUE;

EID: 0034791237     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115040-00002     Document Type: Review

References (55)

1. Fate of protein containing liposomes injected into rats. An approach to the treatment of storage diseases
2. Lysosomal localization of fructofuranoside-containing liposomes injected into rats
3. In vivo distribution of liposomes between parenchymal and non-parenchymal cells in rat liver
4. The involvement of parenchymal, Kupffer and endothelial liver cells in hepatic uptake of intravenously injected liposomes. Effect of lanthanum and gadolinium salts
5. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine
6. Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362
7. Serum opsonins and liposomes: Their interaction and opsonophagocytosis
8. Complement dependent phagocytosis of liposomes: Suppression of 'stealth' lipids
9. Large unilamellar liposomes with low uptake into the reticuloendothelial system
10. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
11. Liposomes for the sustained drug release
12. How do polymers prolong circulation time of liposomes?
13. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes
14. Effect of molecular weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes
15. Activity of amphipathic poly (ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target
16. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system
17. Intrahepatic distribution of long circulating liposomes containing poly (ethylene glycol) distearoyl phosphatidylethanolamine
18. Vascular and interstitial barriers to delivery of therapeutic agents in tumors
19. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice
20. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft
21. Liposomal doxorubicin: Antitumor activity and unique toxicities during complementary phase I studies
22. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A
23. 2to vesicle surface
24. Uptake and processing of immunoglobulin-coated liposomes by sub-populations of rat liver macrophages
25. Influence of the steric barrier activity of amphipathic poly (ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo
26. Antibody-targeted stealth liposomes
27. Attachment of antibodies to sterically stabilized liposomes: Evaluation, comparison and optimization of coupling procedures
28. Targetability of novel immunoliposomes modified with amphipathic poly (ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies
29. Synthesis of end-group functionalized polyethylene glycol-lipid conjugates for preparation of polymer-grafted liposomes
30. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells
31. Targetability of novel immunoliposomes prepared by a new antibody conjugation technique
32. Antibody-mediated targeting of long-circulating (Stealth®) liposomes
33. Sterically stabilized anti HER-2 immunoliposomes: Design and targeting to human breast cancer cells in vitro
34. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo
35. + leukocytes is dependent on immune status
36. Immunogenicity of immunoliposomes: Reactivity against species-specific IgG and liposomal phospholipids
37. Immunogenicity and pharmacokinetic attributes of poly (ethylene glycol)-grafted immunoliposomes
38. Biosynthetic lipid-tagging of antibodies
39. Functional immunoliposomes harboring a biosynthetically lipid-tagged single-chain antibody
40. Biosynthetically lipid-modified human scFv fragmems from phage display libraries as targeting molecules for immunoliposomes
41. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro
42. Development of anti-p185 HER-2 immunoliposomes for cancer therapy
43. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells
44. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells
45. Lipid composition is important for highly efficient target binding and retention of immunoliposomes
46. Sterically stabilized anti GM3, anti Lex immunoliposomes: Targeting to B16BL6, HRT-18 cancer cells
47. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: Pharmacokinetic and biodistribution in tumor-bearing mice
48. Anti HER-2 immunoliposomes for targeted therapy of human tumors
49. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo
50. Antibody-targeted delivery of doxorubicin-entrapped in sterically stabilized liposomes can eradicate lung cancer in mice
51. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma
52. Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): Optimization of prodrug activating capacity
53. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD (2)-targeted immunoliposomes: Antitumor effect
54. Noninvasive gene targeting to the brain
55. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide